Compare Sun Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs IPCA LABS - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA IPCA LABS SUN PHARMA/
IPCA LABS
 
P/E (TTM) x 26.6 21.4 124.5% View Chart
P/BV x 2.3 4.2 55.5% View Chart
Dividend Yield % 0.7 0.1 614.0%  

Financials

 SUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
IPCA LABS
Mar-18
SUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs679695 97.6%   
Low Rs375400 93.9%   
Sales per share (Unadj.) Rs121.1260.2 46.6%  
Earnings per share (Unadj.) Rs13.419.0 70.5%  
Cash flow per share (Unadj.) Rs20.733.1 62.6%  
Dividends per share (Unadj.) Rs2.751.00 275.0%  
Dividend yield (eoy) %0.50.2 285.7%  
Book value per share (Unadj.) Rs172.6213.0 81.0%  
Shares outstanding (eoy) m2,399.26126.20 1,901.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.1 206.7%   
Avg P/E ratio x39.428.9 136.5%  
P/CF ratio (eoy) x25.516.6 153.8%  
Price / Book Value ratio x3.12.6 118.8%  
Dividend payout %20.65.3 390.0%   
Avg Mkt Cap Rs m1,264,65069,120 1,829.7%   
No. of employees `00017.513.3 132.0%   
Total wages/salary Rs m59,6717,359 810.9%   
Avg. sales/employee Rs Th16,608.12,477.4 670.4%   
Avg. wages/employee Rs Th3,409.6555.2 614.1%   
Avg. net profit/employee Rs Th1,833.8180.6 1,015.2%   
INCOME DATA
Net Sales Rs m290,65932,836 885.2%  
Other income Rs m10,255418 2,453.3%   
Total revenues Rs m300,91433,254 904.9%   
Gross profit Rs m63,0764,505 1,400.2%  
Depreciation Rs m17,5331,777 986.5%   
Interest Rs m5,553240 2,311.6%   
Profit before tax Rs m50,2462,905 1,729.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,009511 1,175.7%   
Profit after tax Rs m32,0932,394 1,340.5%  
Gross profit margin %21.713.7 158.2%  
Effective tax rate %12.017.6 68.0%   
Net profit margin %11.07.3 151.4%  
BALANCE SHEET DATA
Current assets Rs m310,69219,455 1,597.0%   
Current liabilities Rs m173,39610,076 1,720.9%   
Net working cap to sales %47.228.6 165.4%  
Current ratio x1.81.9 92.8%  
Inventory Days Days9998 101.2%  
Debtors Days Days11267 166.6%  
Net fixed assets Rs m232,47720,260 1,147.5%   
Share capital Rs m2,399252 950.6%   
"Free" reserves Rs m411,69126,633 1,545.8%   
Net worth Rs m414,09126,886 1,540.2%   
Long term debt Rs m15,2262,340 650.7%   
Total assets Rs m646,93841,173 1,571.3%  
Interest coverage x10.013.1 76.7%   
Debt to equity ratio x00.1 42.2%  
Sales to assets ratio x0.40.8 56.3%   
Return on assets %5.86.4 90.9%  
Return on equity %7.88.9 87.0%  
Return on capital %10.210.8 94.5%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m66,02515,642 422.1%   
Fx outflow Rs m38,6104,884 790.6%   
Net fx Rs m27,41510,759 254.8%   
CASH FLOW
From Operations Rs m21,9653,411 643.9%  
From Investments Rs m-6,813-1,354 503.1%  
From Financial Activity Rs m-27,305-1,304 2,093.8%  
Net Cashflow Rs m-8,442753 -1,120.8%  

Share Holding

Indian Promoters % 63.7 45.9 138.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.4 45.0%  
FIIs % 23.0 25.3 90.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.4 47.7%  
Shareholders   133,026 36,892 360.6%  
Pledged promoter(s) holding % 0.5 2.1 24.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Oct 15, 2019 03:37 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS